Phase 0: legislative design and technical assistance
Before filing, request meetings with legislative counsel and relevant committee staff to settle the scope of the bill: procedural access only or a genuinely new investigational route. Request FDA and HHS technical assistance on current sponsor paths, review requirements and the implications of proposed data rights. Obtain a table of amendments to 21 USC and related regulations and a rigorous account of current administrative authorities.
Collect documented barriers from independent investigators, community clinics, academic trial operators and participants. Each example should include what was attempted, the relevant authority, a written decision if available, cost and time, and the change that might have solved it. This is stronger testimony than general claims of being excluded from science.
The legislative packet should include a one-page ask, this evidence dossier, a legal current-law matrix, proposed options, a conflict/interest statement, peer-reviewed research references, draft statutory instructions, a privacy model, a pilot evaluation design and a request for outside counsel review. No testimony should represent AI agent outputs as independently licensed legal opinions.
Phase 1: administration and research-access service
Following authorization and appropriation, a responsible federal program can publish an eligibility and pathway guide, small-sponsor checklist, clear filing templates, a directory of support services and a defined process for written regulatory classification requests. The Act should specify time clocks and reporting deadlines if Congress wants more than voluntary agency guidance.
An independent scientific and privacy advisory committee can establish methodological expectations, participant experience measures and initial metrics. The program should publish accessibility requirements so that rural applicants, people with disabilities and participants lacking high-bandwidth internet can use it. FDA's 2025 guidance on participation and representativeness supports treating access barriers as a scientific design issue. F21
Early non-interventional demonstration projects could validate data-quality processes, participant communication, secure permission records and reporting tools without claiming new drug-intervention permission. They can reveal feasibility, privacy and cost problems before an interventional pilot is considered.
Phase 2: controlled pilots and evaluation
A second phase could test supported small-sponsor lawful clinical investigations within existing IND and review frameworks. If Congress creates a new tailored route, that work should begin only after clear product-quality rules, incident processes, funding and defined oversight are in force. A pilot's name is not its authorization. F01F03F05
Pilot evaluation should include a preregistered comparison plan: applicant time and direct cost, appropriate reviewer access, completeness of methods documentation, participant comprehension, dropout, protocol deviations, adverse events, publication of unfavorable outcomes, and governance complaints. The analytical plan should distinguish differences caused by participant selection from differences caused by the program.
Funding approaches include line-item appropriation, competitive grants, small sponsor service fees, or combinations. The program should present cost assumptions openly and request appropriate budget scoring instead of inventing a dollar figure that appears official. Independent contractors or philanthropies may contribute services but should not be allowed to purchase favorable scientific conclusions.
The public oversight dashboard Congress should demand
Useful operator metrics begin with complete research proposals received, regulatory classifications delivered within the specified deadline, reasons for denied or returned applications, and median applicant cost. These tell lawmakers whether the legal route is usable, not merely whether the website attracts attention.
Scientific metrics include registered protocols, independently reviewed designs, completed safety follow-up, outcomes with uncertainty estimates, reproducibility submissions, and the share of studies reporting null results. Participant measures should include accurate consent comprehension, portability and withdrawal response, complaints and remediation.
Privacy indicators should show verified unauthorized disclosures, average time to contain incidents, proportion of access grants honoring purpose and expiry, security audit coverage and unresolved obligations. The dashboard should include confidence intervals or appropriate qualifiers where sample sizes are small.
The first mandated congressional report could compare actual program outcomes against a published preimplementation baseline. It should name what did not improve and recommend targeted rule or statutory changes. No amount of traffic, public excitement or petition signatures proves a clinical research outcome.
The key questions for a congressional hearing
Ask FDA what tasks individual sponsors can already complete and where they face documented administrative or financial barriers; what product-quality evidence is indispensable for distinct classes of investigation; and whether a limited support program can operate within present law. Ask HHS and OHRP how independent review and reliance agreements apply to distributed teams.
Ask methodologists which patient-led and decentralized approaches reliably improve participation and which have weak comparative evidence. Ask privacy engineers what can be enforced after de-identification or downstream data export, and ask insurers whether financial-responsibility requirements are feasible for small sponsors.
Ask independent citizens what concrete burdens they face, but distinguish their preferences from evidence of an existing legal barrier. The committee should learn which rules need amendment, which systems need funding, and which claims remain unresolved.